首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Selective inhibition of CD4~+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors
【24h】

Selective inhibition of CD4~+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors

机译:BET蛋白和c-Myc抑制剂对CD4〜+ T细胞细胞因子产生和自身免疫的选择性抑制

获取原文
获取原文并翻译 | 示例
       

摘要

Bromodomain-containing proteins bind acetylated lysine residues on histone tails and are involved in the recruitment of additional factors that mediate histone modifications and enable transcription. A compound, l-BET-762, that inhibits binding of an acetylated histone peptide to proteins of the bromodomain and extra-terminal domain (BET) family, was previously shown to suppress the production of proinflammatory proteins by macrophages and block acute inflammation in mice. Here, we investigated the effect of short-term treatment with l-BET-762 on T-cell function. Treatment of naive CD4~+ T cells with l-BET-762 during the first 2 d of differentiation had long-lasting effects on subsequent gene expression and cytokine production. Gene expression analysis revealed up-regulated expression of several antiinflammatory gene products, including IL-10, Lag3, and Egr2, and down-regulated expression of several proinflammatory cytokines including GM-CSF and IL-17. The short 2-d treatment with l-BET-762 inhibited the ability of antigen-specific T cells, differentiated under Th1 but not Th17 conditions in vitro, to induce pathogenesis in an adoptive transfer model of experimental autoimmune encephalomyelitis. The suppressive effects of l-BET-762 on T-cell mediated inflammation in vivo were accompanied by decreased recruitment of macrophages, consistent with decreased GM-CSF production by CNS-infiltrating T cells. These effects were mimicked by an inhibitor of c-myc function, implicating reduced expression of c-myc and GM-CSF as one avenue by which l-BET-762 suppresses the inflammatory functions of T cells. Our study demonstrates that inhibiting the functions of BET-family proteins during early T-cell differentiation causes long-lasting suppression of the proinflammatory functions of Th1 cells.
机译:含溴结构域的蛋白质与组蛋白尾巴上的乙酰化赖氨酸残基结合,并参与介导组蛋白修饰并实现转录的其他因子的募集。先前显示,抑制乙酰化组蛋白肽与溴结构域和末端外结构域(BET)家族蛋白结合的化合物l-BET-762可抑制巨噬细胞促炎蛋白的产生并阻断小鼠的急性炎症。在这里,我们调查了短期治疗l-BET-762对T细胞功能的影响。在分化的前2天,用l-BET-762处理幼稚的CD4〜+ T细胞,对随后的基因表达和细胞因子产生具有持久的影响。基因表达分析揭示了包括IL-10,Lag3和Egr2在内的几种抗炎基因产物的表达上调,以及包括GM-CSF和IL-17在内的几种促炎细胞因子的表达下调。用l-BET-762进行的短短2 d处理在实验性自身免疫性脑脊髓炎的过继转移模型中抑制了在Th1条件下而非Th17条件下体外分化的抗原特异性T细胞诱导发病的能力。 l-BET-762对体内T细胞介导的炎症的抑制作用伴随着巨噬细胞募集的减少,这与CNS浸润T细胞产生的GM-CSF减少相一致。这些作用被c-myc功能抑制剂模仿,暗示c-myc和GM-CSF的表达减少是l-BET-762抑制T细胞炎症功能的一种途径。我们的研究表明,在早期T细胞分化过程中抑制BET家族蛋白的功能会导致Th1细胞促炎功能的长期抑制。

著录项

  • 来源
  • 作者单位

    La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037,lmmune Disease Institute, Harvard Medical School and Program in Cellular and Molecular Medicine, Children's Hospital Boston, Boston, MA 02115,Department of Pharmacology, University of California at San Diego, La Jolla, CA 92037;

    lmmune Disease Institute, Harvard Medical School and Program in Cellular and Molecular Medicine, Children's Hospital Boston, Boston, MA 02115;

    La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037;

    La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037;

    lmmune Disease Institute, Harvard Medical School and Program in Cellular and Molecular Medicine, Children's Hospital Boston, Boston, MA 02115;

    Epinova DPU, Immuno-lnflammation Therapeutic Area and QSCi Computational Biology, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom;

    Epinova DPU, Immuno-lnflammation Therapeutic Area and QSCi Computational Biology, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom;

    Epinova DPU, Immuno-lnflammation Therapeutic Area and QSCi Computational Biology, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom;

    Epinova DPU, Immuno-lnflammation Therapeutic Area and QSCi Computational Biology, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom;

    Epinova DPU, Immuno-lnflammation Therapeutic Area and QSCi Computational Biology, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom;

    Epinova DPU, Immuno-lnflammation Therapeutic Area and QSCi Computational Biology, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom;

    Epinova DPU, Immuno-lnflammation Therapeutic Area and QSCi Computational Biology, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom;

    La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037;

    La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037,lmmune Disease Institute, Harvard Medical School and Program in Cellular and Molecular Medicine, Children's Hospital Boston, Boston, MA 02115,Department of Pharmacology, University of California at San Diego, La Jolla, CA 92037,Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    positive transcription elongation factor b; BRD4; 5; 6-dichloro-1-β-D-ribofuranosylbenzimidazole; BRD inhibitors; transcriptional pausing;

    机译:正转录延伸因子b;BRD4;5;6-二氯-1-β-D-呋喃呋喃糖基苯并咪唑;BRD抑制剂;转录暂停;
  • 入库时间 2022-08-18 00:40:27

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号